{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"study_type":["Other"],"full_dataset_link":["https://ega-archive.org/studies/EGAS00001006037"],"host":["EGA"],"description":["EGA study EGAS00001006037"],"dataset_title":["Clinical data","Biomarker data"],"category":["restricted"],"repository":["EGA"],"additional_accession":[]},"is_claimable":false,"name":"The KATHERINE study of adjuvant trastuzumab emtansine in HER2-positive breast cancer: analysis of patients with HER2-negative residual invasive disease on re-testing","description":"Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 and trastuzumab in patients randomized in the phase III KATHERINE trial based on HER2-positive central testing of the core biopsy with HER2-negative central testing on their corresponding surgical specimen.   In the 70/845 (8.3%) patients with HER2-negative residual disease on retesting at surgery, there were 11 IDFS events in the 42 trastuzumab-treated patients (26.2%) and none in the 28 T-DM1-treated patients, suggesting that T-DM1 should not be withheld in this patient population.","dates":{"updated":"2022-09-22 12:32:09"},"accession":"EGAS00001006037","cross_references":{"TAXONOMY":["9606"],"EGA":["EGAD00001009415","EGAD00001009414","EGAC00001002871"]}}